- Home
- CHRO vs CWD Comparison
CHRO vs CWD Comparison
Compare CHRO & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- CWD
- Stock Information
- Founded
- CHRO 2002
- CWD 2009
- Country
- CHRO United States
- CWD United States
- Employees
- CHRO N/A
- CWD N/A
- Industry
- CHRO
- CWD Real Estate
- Sector
- CHRO
- CWD Finance
- Exchange
- CHRO Nasdaq
- CWD Nasdaq
- Market Cap
- CHRO 10.7M
- CWD 12.1M
- IPO Year
- CHRO 2024
- CWD 2023
- Fundamental
- Price
- CHRO $1.45
- CWD $0.54
- Analyst Decision
- CHRO Strong Buy
- CWD
- Analyst Count
- CHRO 1
- CWD 0
- Target Price
- CHRO N/A
- CWD N/A
- AVG Volume (30 Days)
- CHRO 8.2K
- CWD 244.5K
- Earning Date
- CHRO 03-27-2025
- CWD 03-31-2025
- Dividend Yield
- CHRO N/A
- CWD N/A
- EPS Growth
- CHRO N/A
- CWD N/A
- EPS
- CHRO N/A
- CWD N/A
- Revenue
- CHRO N/A
- CWD $51,119,000.00
- Revenue This Year
- CHRO N/A
- CWD N/A
- Revenue Next Year
- CHRO N/A
- CWD $33.62
- P/E Ratio
- CHRO N/A
- CWD N/A
- Revenue Growth
- CHRO N/A
- CWD N/A
- 52 Week Low
- CHRO $0.45
- CWD $0.37
- 52 Week High
- CHRO $3.80
- CWD $1.05
- Technical
- Relative Strength Index (RSI)
- CHRO 43.38
- CWD 42.49
- Support Level
- CHRO $1.34
- CWD $0.54
- Resistance Level
- CHRO $2.00
- CWD $0.68
- Average True Range (ATR)
- CHRO 0.17
- CWD 0.09
- MACD
- CHRO -0.02
- CWD -0.01
- Stochastic Oscillator
- CHRO 16.58
- CWD 22.23
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.